CS1 expanded access program for PAH now covers 10 patients
Cereno's expanded access program for investigational therapy CS1 covers 10 PAH patients, following a Phase 2a clinical trial.| Pulmonary Hypertension News
Cereno's expanded access program for investigational therapy CS1 covers 10 PAH patients, following a Phase 2a clinical trial.| Pulmonary Hypertension News
The investigational therapy CS1 led to beneficial changes in for people with pulmonary arterial hypertension in a Phase 2a clinical trial.| Pulmonary Hypertension News
A 5-year-old boy with a neuroblastoma developed PAH after receiving a high dose of chemotherapy to prepare for a stem cell transplant.| Pulmonary Hypertension News
In hypoxic pulmonary hypertension, exosomes derived from stem cells may be a therapy option for preventing abnormal muscle cell growth.| Pulmonary Hypertension News
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Pulmonary Hypertension News
Category archive page for News.| Pulmonary Hypertension News
A pivotal study testing Sensydia's noninvasive device, which may help diagnose pulmonary hypertension, enrolled its first participant.| Pulmonary Hypertension News
